Gregoriadis G, Ryman B E
Biochem J. 1972 Aug;129(1):123-33. doi: 10.1042/bj1290123.
Yeast beta-fructofuranosidase (invertase) or (131)I-labelled albumin were entrapped into liposomes composed of phosphatidylcholine, cholesterol and phosphatidic acid. Of the beta-fructofuranosidase activity in the liposomal preparations 96-100% was latent. The following observations were made in experiments with rats injected with protein-containing liposomes. 1. After injection of beta-fructofuranosidase-containing liposomes (220 units or 1.5mg of beta-fructofuranosidase and 17.5mg of lipid), beta-fructofuranosidase activity in blood retained its latency but the activity declined to 50% of the injected dose in 1h. Within 6h much of this activity was recovered in the liver and spleen (respectively 45% and 10% of that injected). For up to 21h after injection, the mitochondrial-lysosomal fraction was the principal location of the hepatic beta-fructofuranosidase activity. 2. Lysosomal localization of liposomal protein was supported by the observed increase in the trichloroacetic acid-soluble radioactivity during incubation of the lysosome-rich fraction of the liver of rats injected with liposomes containing (131)I-labelled albumin. 3. Association of liposomal protein with lysosomes was demonstrated on subfractionation of the mitochondrial-lysosomal fraction of the liver of rats injected with beta-fructofuranosidase-containing liposomes in a Ficoll-mannitol gradient. beta-Fructofuranosidase, lysosomal and mitochondrial enzyme marker activities were found to exhibit similar distribution patterns along the gradient. However, in similar experiments with rats previously injected with Triton WR-1339 or dextran (known to alter the specific gravity of lysosomes), only beta-fructofuranosidase and lysosomal marker moved along the gradient, in strikingly similar patterns. 4. The lysosomal localization of injected liposome-entrapped material can probably be utilized in the treatment of certain disorders in man.
将酵母β-呋喃果糖苷酶(转化酶)或(131)I标记的白蛋白包裹于由磷脂酰胆碱、胆固醇和磷脂酸组成的脂质体中。脂质体制剂中96 - 100%的β-呋喃果糖苷酶活性呈潜伏状态。在用注射含蛋白质脂质体的大鼠进行的实验中观察到以下情况。1. 注射含β-呋喃果糖苷酶的脂质体(220单位或1.5毫克β-呋喃果糖苷酶和17.5毫克脂质)后,血液中的β-呋喃果糖苷酶活性保持潜伏状态,但活性在1小时内降至注射剂量的50%。6小时内,大部分这种活性在肝脏和脾脏中恢复(分别为注射量的45%和10%)。注射后长达21小时,线粒体-溶酶体部分是肝脏β-呋喃果糖苷酶活性的主要部位。2. 在用注射含(131)I标记白蛋白的脂质体的大鼠肝脏富含溶酶体部分孵育期间,观察到三氯乙酸可溶性放射性增加,这支持了脂质体蛋白的溶酶体定位。3. 在含β-呋喃果糖苷酶的脂质体注射的大鼠肝脏线粒体-溶酶体部分在Ficoll-甘露醇梯度中进行亚分级分离时,证明了脂质体蛋白与溶酶体的关联。发现β-呋喃果糖苷酶、溶酶体和线粒体酶标记活性沿梯度呈现相似的分布模式。然而,在先前注射曲拉通WR - 1339或葡聚糖(已知会改变溶酶体的比重)的大鼠的类似实验中,只有β-呋喃果糖苷酶和溶酶体标记物沿梯度移动,且模式极为相似。4. 注射的脂质体包裹物质的溶酶体定位可能可用于人类某些疾病的治疗。